Hebei Changshan Biochemical Pharmaceutical Co., Ltd is principally engaged in the research, development, manufacture and distribution of bio-pharmaceutical products. The Company primarily provides heparin product series. The Company provides sodium heparin active pharmaceutical ingredients (APIs) and hydro-acupuncture preparations. The Company's products are applied primarily in the prevention and treatment of cerebral vascular diseases, hardened arteries, myocardial infarction and phlebitis, among others. It distributes its products in domestic and overseas markets.

Employees

1,254

Sector

Pharmaceuticals

Calendar

04-21 - Q4 2025 Earnings Release (Projected)

More about the company

Quotes

Date	Price	Change	Volume
10/12/25	66.99 ¥	+4.02%	21,722,830
09/12/25	64.40 ¥	-1.08%	13,913,080
08/12/25	65.10 ¥	-2.78%	23,937,920
05/12/25	66.96 ¥	-0.96%	17,068,620
04/12/25	67.61 ¥	+3.25%	21,998,570

End-of-day quote Shenzhen S.E., December 09, 2025

More quotes

Income Statement and Estimates

More financial data

End-of-day quote Shenzhen S.E. Other stock markets 10/12/2025			5-day change	1st Jan Change
66.99 ^CNY	+4.02%		+2.31%	+235.12%

11-21	Hebei Changshan Biochemical Pharmaceutical's controlling shareholder to sell 5% stake	RE
10-29	Hebei Changshan Biochemical Pharmaceutical Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2025	CI

Capitalization	61.57B 8.72B 7.48B 7B 6.54B 12.06B 783B 13.13B 81.15B 31.62B 371B 32.71B 32.01B 1,363B	P/E ratio 2023	-9.64x	P/E ratio 2024	-74x
Enterprise value	63.87B 9.04B 7.76B 7.26B 6.78B 12.52B 813B 13.62B 84.19B 32.8B 385B 33.93B 33.21B 1,414B	EV / Sales 2023	9.99x	EV / Sales 2024	20.1x
Free-Float	50.4%	Yield 2023 *	-	Yield 2024	-

11-21	Hebei Changshan Biochemical Pharmaceutical's controlling shareholder to sell 5% stake	RE
10-29	Hebei Changshan Biochemical Pharmaceutical Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2025	CI
09-22	Hebei Changshan Biochemical Pharmaceutical Co., Ltd.(XSEC:300255) added to FTSE All-World Index	CI
08-25	Changshan Biochemical Pharmaceutical Narrows H1 Loss; Shares Jump 13%	MT
08-22	Hebei Changshan Biochemical Pharmaceutical Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2025	CI
06-16	Hebei Changshan Biochemical Pharmaceutical Co., Ltd.(SZSE:300255) added to Shenzhen Stock Exchange Component A Share Index	CI
06-15	Hebei Changshan Biochemical Pharmaceutical Co., Ltd.(SZSE:300255) added to Shenzhen Stock Exchange Component Index	CI
05-21	Changshan Biochemical Pharma's Nadroparin Calcium Injection Gets Registration Certificate from Belarus' Drug Regulator	MT
04-28	Hebei Changshan Biochemical Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2025	CI
04-28	Hebei Changshan Biochemical Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2024	CI
02-14	Changshan Biochemical Pharmaceutical Enrolls First Patient in Drug Trial	MT
12-30	Hebei Changshan Biochemical Pharmaceutical Co., Ltd. Approves Management Appointments	CI
11-20	Changshan Biochemical Pharma Shareholder Trims Stake	MT

1 day	+4.02%
1 week	+2.31%
Current month	+7.79%
1 month	+25.73%
3 months	+41.45%
6 months	+32.78%
Current year	+235.12%

Hebei Changshan Biochemical Pharmaceutical Co., Ltd. Share Price

Equities

300255

CNE1000016C2

Pharmaceuticals

Valuation: Hebei Changshan Biochemical Pharmaceutical Co., Ltd.

Chart: Hebei Changshan Biochemical Pharmaceutical Co., Ltd.

Latest news: Hebei Changshan Biochemical Pharmaceutical Co., Ltd.

Quotes and Performance

Course Extremes

Managers and Directors: Hebei Changshan Biochemical Pharmaceutical Co., Ltd.

Biopharmaceuticals

Financials

Company Profile

Quotes

Income Statement and Estimates

1 week	63	67.68
1 month	50.8	68.5
Current year	15.75	71.71
1 year	15.75	71.71
3 years	4.3	71.71
5 years	4.3	71.71
10 years	3.88	71.71

Manager	Title	Age	Since
Xiao Dong Gao CEO	Chief Executive Officer	52	12/05/2019
Xiao Hua Yue DFI	Director of Finance/CFO	54	05/11/2023
Zheng Gang Qie PRN	Corporate Officer/Principal	54	23/06/2020

Director	Title	Age	Since
Jin Liang Wang BRD	Director/Board Member	59	19/09/2016
Yun Xia Sun BRD	Director/Board Member	44	19/05/2021
De Ying Cao BRD	Director/Board Member	66	07/08/2011

	2023	2024
Net sales	1.41B 200M 171M 160M 150M 276M 17.95B 301M 1.86B 724M 8.51B 749M 733M 31.22B	1.03B 146M 125M 117M 109M 202M 13.12B 220M 1.36B 529M 6.22B 548M 536M 22.82B
Net income	-1.24B -176M -151M -141M -132M -243M -15.78B -264M -1.63B -637M -7.48B -659M -645M -27.45B	-249M -35.32M -30.32M -28.36M -26.49M -48.88M -3.17B -53.19M -329M -128M -1.5B -133M -130M -5.52B
Net Debt	2.14B 302M 260M 243M 227M 418M 27.18B 455M 2.82B 1.1B 12.88B 1.13B 1.11B 47.28B	2.31B 326M 280M 262M 245M 452M 29.33B 491M 3.04B 1.18B 13.9B 1.22B 1.2B 51.02B

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5d. change	1-year change	3-years change	Capi.($)
HEBEI CHANGSHAN BIOCHEMICAL PHARMACEUTICAL CO., LTD.	+4.02%	+2.31%	+221.91%	+996.40%	8.72B
REGENERON PHARMACEUTICALS, INC.	+4.86%	+0.35%	-6.72%	-3.18%	74.51B
CSL LIMITED	-1.55%	-3.66%	-36.05%	-40.04%	58.22B
UCB	-0.66%	+0.29%	+33.70%	+233.33%	53.6B
SAMSUNG BIOLOGICS CO.,LTD.	+0.30%	+66.50%	+66.50%	+66.50%	52.43B
BIOGEN INC.	+0.97%	-1.77%	+13.58%	-37.78%	26.05B
INCYTE CORPORATION	+0.01%	-6.24%	+31.31%	+15.58%	18.68B
INNOVENT BIOLOGICS, INC.	+0.18%	-10.58%	+118.98%	+161.41%	18.39B
ALTEOGEN INC.	-0.11%	-12.55%	+43.55%	+1,012.06%	16.61B
INTRA-CELLULAR THERAPIES, INC.	-0.04%	-.--%	+58.67%	+154.72%	14.02B
Average	+0.66%	-2.99%	+54.54%	+255.90%	34.12B
Weighted average by Cap.	+0.81%	-1.54%	+27.26%	+127.07%